SUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up

Launched by INSTITUTO PORTUGUES DE ONCOLOGIA, FRANCISCO GENTIL, PORTO · Oct 30, 2020

Keywords

ClinConnect Summary

This clinical trial, called the SUrveillance of PREMalignant Stomach, is focused on patients who have conditions that could lead to stomach cancer, such as atrophic gastritis and intestinal metaplasia. The researchers want to better understand how to monitor these patients by using different methods to assess the condition of their stomach lining and to determine how often they should have follow-up procedures. The goal is to find the best way to keep track of patients at risk for gastric cancer and make sure they receive the right care at the right time.

To participate in this study, individuals must be over 45 years old and scheduled for an upper gastrointestinal endoscopy, which is a procedure that allows doctors to look inside the stomach. Participants will undergo a thorough evaluation, including biopsies (tissue samples) if needed, and will be grouped based on the severity of their condition. Depending on their results, they may have follow-up endoscopies every year or every few years for up to six years. It’s important to know that patients with certain high-risk factors or previous severe gastric issues may not be eligible for this trial. This study is currently recruiting participants, and it aims to enhance our understanding of stomach health and cancer prevention.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients scheduled for upper GI endoscopy with indication for gastric biopsies, including those with known gastric pathology (e.g. auto-immune gastritis) or premalignant conditions (e.g patients under surveillance because of atrophic gastritis);
• • Age above 45 years old
• Exclusion Criteria:
• • History of previous gastrectomy;
• • History of endoscopic resection of neoplastic lesion
• • History of previous gastric dysplasia (even with no detectable lesion)
• • Hereditary syndromes that increase gastric cancer risk (familial adenomatous polyposis; Lynch syndrome)
• • Serious comorbidities (ASA 3 or more)
• • Medication with anticoagulants